Fragment-based discovery of a potent NAMPT inhibitor.Korepanova, A., Longenecker, K.L., Pratt, S.D., Panchal, S.C., Clark, R.F., Lake, M., Gopalakrishnan, S.M., Raich, D., Sun, C., Petros, A.M.
(2018) Bioorg Med Chem Lett 28: 437-440
- PubMed: 29287958
- DOI: https://doi.org/10.1016/j.bmcl.2017.12.023
- Primary Citation of Related Structures:
- PubMed Abstract:
NAMPT expression is elevated in many cancers, making this protein a potential target for anticancer therapy. We have carried out both NMR based and TR-FRET based fragment screens against human NAMPT and identified six novel binders with a range of potencies. Co-crystal structures were obtained for two of the fragments bound to NAMPT while for the other four fragments force-field driven docking was employed to generate a bound pose. Based on structural insights arising from comparison of the bound fragment poses to that of bound FK866 we were able to synthetically elaborate one of the fragments into a potent NAMPT inhibitor.
Research & Development, AbbVie, 1 North Waukegan Road, North Chicago, IL 60064, United States.